Tag Archives: Eric Althoff

Novartis to divest its influenza vaccines business to CSL Limited (CSL) for USD 275 million

CSL to acquire Novartis influenza vaccines business, including development pipeline, for USD 275 million Announcement follows a transaction announced on April 22, 2014 to divest the non-influenza segments of Novartis Vaccines to GlaxoSmithKline Basel, Switzerland, 28-10-2014 — /EuropaWire/ — Novartis today … Read the full press release

Novartis published clinical trial results about novel and potent antimalarial drug candidate KAE609 (cipargamin)

KAE609 is the first antimalarial drug candidate with a novel mechanism of action to achieve positive clinical proof-of-concept in over 20 years KAE609 was tested in adult patients with uncomplicated malaria and showed a median parasite clearance time of 12 … Read the full press release

US FDA granted breakthrough therapy designation to Novartis’s BYM338 for sporadic inclusion body myositis

Designation highlights potential of BYM338 to address an unmet medical need in a serious disease If approved, BYM338 has the potential to be the first treatment for sIBM patients BYM338 is the third Novartis investigational treatment this year to receive … Read the full press release

Novartis invites 60 selected students from leading international universities to its headquarters in Switzerland for the International Biotechnology Leadership Camp

The International Biotechnology Leadership Camp (BioCamp) fosters idea exchange with leading scientists as well as entrepreneurship for young talents 60 selected students from leading international universities attend to explore science and innovation at Novartis headquarters in Basel, Switzerland Novartis CEO … Read the full press release